The average one-year price target for A.P. Møller - Mærsk A (WBAG:MRSA) has been revised to € 1.662,66 / share. This is an increase of 10.50% from the prior estimate of € 1.504,72 dated July 17, 2025.

The price target is an average of many targets provided by analysts. The latest targets range from a low of € 1.265,87 to a high of € 2.324,00 / share. The average price target represents an increase of 0.77% from the latest reported closing price of € 1.650,00 / share.

What is the Fund Sentiment?

There are 199 funds or institutions reporting positions in A.P. Møller - Mærsk A. This is an increase of 6 owner(s) or 3.11% in the last quarter. Average portfolio weight of all funds dedicated to MRSA is 0.09%, an increase of 22.56%. Total shares owned by institutions increased in the last three months by 11.68% to 279K shares.

What are Other Shareholders Doing?

VGTSX - Vanguard Total International Stock Index Fund Investor Shares holds 43K shares representing 0.44% ownership of the company. No change in the last quarter.

VTMGX - Vanguard Developed Markets Index Fund Admiral Shares holds 29K shares representing 0.30% ownership of the company. In its prior filing, the firm reported owning 29K shares , representing an increase of 0.72%. The firm increased its portfolio allocation in MRSA by 0.08% over the last quarter.

IDV - iShares International Select Dividend ETF holds 28K shares representing 0.29% ownership of the company. In its prior filing, the firm reported owning 14K shares , representing an increase of 49.37%. The firm increased its portfolio allocation in MRSA by 96.63% over the last quarter.

IEFA - iShares Core MSCI EAFE ETF holds 17K shares representing 0.18% ownership of the company. In its prior filing, the firm reported owning 17K shares , representing an increase of 0.83%. The firm increased its portfolio allocation in MRSA by 10.30% over the last quarter.

EFA - iShares MSCI EAFE ETF holds 10K shares representing 0.10% ownership of the company. In its prior filing, the firm reported owning 10K shares , representing an increase of 2.32%. The firm increased its portfolio allocation in MRSA by 11.45% over the last quarter.